A former Gilead Sciences Inc. COO says in new court papers that a lawsuit filed against him by a former aide should be transferred to Ventura County, saying he had no personal or business ties to Los ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Gilead Sciences (GILD) concluded the recent trading session at $88.82, signifying a +0.6% move from its prior day's close.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Modera Wealth Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 8.9% in ...

Mount Gilead's boys cross country team won the Division III state championship Saturday morning at Fortress Obetz, plus other ...

Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

PICKERINGTON — Mount Gilead proved an old cross country axiom true: Every place, every second and every step counts. During ...